| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $85.1M | +48.8% |
| SG&A Expense | $27.3M | +73.7% |
| Operating Income | -$112.4M | -54.2% |
| Net Income | -$108.5M | -46.7% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $54.9M | -84.1% |
| Current Assets | $275.9M | -20.9% |
| Total Assets | $342.4M | -6.5% |
| Current Liabilities | $25.6M | +53.7% |
| Total Liabilities | $71.0M | +277.3% |
| Stockholders' Equity | $271.4M | -21.9% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$92.5M | -55.8% |
| Capital Expenditures | $12.9M | +32.7% |
| Investing Cash Flow | -$219.2M | -2171.0% |
| Financing Cash Flow | $20.5M | -94.6% |
| Free Cash Flow | -$105.4M | -52.5% |